Vaccine Research
Return to Library
|
Free Vaccine Research Articles |
|
|
|
|
Scientists at National Institutes of Health detail research in adenovirus
2009 JUL 20 - (NewsRx.com) -- According to a study from the United States, "The magnitude and character of adenovirus serotype 5 (Ad5)-specific T cells were determined in volunteers with and without preexisting neutralizing antibodies (NAs) to Ad5 who received replication-defective Ad5 (rAd5)-based human immunodeficiency virus vaccines." "There was no correlation between T-cell responses and NAs to Ad5. There was no increase in magnitude or activation state of Ad5-specific CD4(+) T cells at time points where antibodies to Ad5 and T-cell responses to the recombinant gene products could be measured," wrote R.A. Koup and colleagues, National Institutes of Health. The researchers concluded: "These data indicate that rAd5-based vaccines containing deletions in the E1, E3, and E4 regions do not induce appreciable expansion of vector-specific CD4(+) T cells." Koup and colleagues published their study in the Journal of Virology (Replication-Defective Adenovirus Vectors with Multiple Deletions Do Not Induce Measurable Vector-Specific T Cells in Human Trials. Journal of Virology, 2009;83(12):6318-6322). For more information, contact R.A. Koup, NIAID, Immunology Laboratory, Vaccine Research Center, National Institutes of Health, 40 Convent Dr., MSC 3022, Bldg 40, Room 3502, Bethesda, MD 20892, USA. Publisher contact information for the Journal of Virology is: American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA. Keywords: United States, Bethesda, Adenovirus, AIDS, Acquired Immune Deficiency Syndrome, Adenoviridae, Biotechnology, Gene Therapy, HIV, Human Immunodeficiency Virus, Immunization, Immunology, Sexually Transmitted Disease, Vaccines, Viral, Virology, National Institutes of Health. This article was prepared by AIDS Weekly editors from staff and other reports. Copyright 2009, AIDS Weekly via NewsRx.com.
|
